RCKT Q3 2022 Earnings — Rocket Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RCKTRocket Pharmaceuticals, Inc.

$572M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$58M

Net Income

-$58M

EPS (Diluted)

$-0.86

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$44M

Free Cash Flow

-$44M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$417M

Total Liabilities

$50M

Stockholders' Equity

$367M

Cash & Equivalents

$197M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$58M	-$50M	-17.8%
Net Income	-$58M	-$50M	-15.2%